|Bid||5.01 x 1800|
|Ask||5.03 x 1100|
|Day's Range||4.91 - 5.22|
|52 Week Range||3.81 - 19.60|
|Beta (3Y Monthly)||1.22|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.29|
Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced the completion of an amendment to its loan and security agreement with Hercules Capital, Inc. (“Hercules”). The amendment provides for a 9-month interest-only period commencing December 2019, as well as the elimination of the covenant to maintain a minimum cash balance.
The FDA grants Orphan Drug status to Axovant's (AXGT) gene therapy candidate, AXO-AAV-GM1, being developed for the treatment of GM1 gangliosidosis. Shares decline despite the positive news.
Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company’s investigational gene therapy, AXO-AAV-GM1, for the treatment of GM1 gangliosidosis. GM1 gangliosidosis is a progressive and fatal pediatric lysosomal storage disorder caused by mutations in the GLB1 gene leading to impaired production of the beta-galactosidase enzyme. “We are pleased to receive orphan drug designation for our GM1 gangliosidosis program as we advance the development of this potentially transformative, one-time gene therapy,” said Dr. Gavin Corcoran, chief R&D officer at Axovant.
Axovant (AXGT) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
First evidence of clinical stabilization in two children with Tay-Sachs disease that received AXO-AAV-GM2 presented at ESGCT in October 2019Continued enrollment of patients in.
A live webcast of the Jefferies and Piper Jaffray conference presentations will be available in the Events section of Axovant's website at www.axovant.com. Replays will be available for approximately 30 days following the conference.
Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced preliminary data from an expanded access study administering investigational AXO-AAV-GM2 gene therapy in two patients with infantile Tay-Sachs disease (TSD) at the 27th Annual Congress of the European Society of Gene and Cell Therapy. Infantile TSD, a rapidly progressive and fatal pediatric neurodegenerative genetic disorder, has a median life expectancy of approximately 3-4 years. This data indicates the potential to modify the rate of disease progression in children with infantile TSD.
Biotech stocks saw some strength last week. Positive clinical readouts, a couple of M&A deals and hopes of drug companies clinching a broader opioid settlement agreement worked in favor of the sector. ...
Axovant Gene Therapies, Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced upcoming presentations regarding its investigational gene therapy programs, AXO-Lenti-PD, AXO-AAV-GM1 and AXO-AAV-GM2, at the European Society of Gene and Cell Therapy (ESGCT) 27th Annual Congress, held in Barcelona, Spain, October 22-25, 2019.
Axovant (AXGT) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BASEL, Switzerland, Sept. 25, 2019 -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Parag.
If you're interested in Axovant Gene Therapies Ltd. (NASDAQ:AXGT), then you might want to consider its beta (a measure...
Axovant's multiple opportunities to find an efficacious gene therapy make it an attractive investment ahead of data readouts scheduled for the fourth quarter, Skorney said in a Monday note. Axovant is due to release initial data from the first Type 2 GM1 gangliosidosis patient dosed with AXO-AAV-GM1 in the fourth quarter. The analyst said the simplistic approach used by AXO-AAV-GM1 in gangliosidosis — usage of well-known AAV9 vector and the IV route of administration — improves the chances of its clinical success.
SUNRISE-PD Phase 2 trial of AXO-LENTI-PD for Parkinson's disease continues to enroll patients in second dose cohort with data expected in the fourth quarter of calendar 2019Data.
IVERIC bio (ISEE) second-quarter earnings improve year over year. The company is focusing on developing gene therapies for treating inherited retinal diseases.